Formulation study of topically applied O/W lotion containing vitamin D3 derivative, focusing on skin permeability of the drug

Drug Development and Industrial Pharmacy

Volumn 37, Issue 8, 2011, Pages 917-925

  Harada, Shin Ichi ^a   Horisawa, Eijiro ^a   Kano, Satoshi ^a   Sugibayashi, Kenji ^b  

^a Maruho Co   (Japan)

^b JOSAI UNIVERSITY   (Japan)

Author keywords

Diffusion; O W lotion; Partition; Skin permeation; Solvent polarity; Topical formulation

Indexed keywords

1,3 BUTANEDIOL; 22 OXACALCITRIOL 1 ALPHA, 25 DIHYDROXYVITAMIN; COLECALCIFEROL DERIVATIVE; MEDIUM CHAIN FATTY ACID; MEDIUM CHAIN FATTY ACID TRIGYCERIDE; MYRISTIC ACID ISOPROPYL ESTER; OIL; PROPYLENE GLYCOL; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ARTICLE; DRUG DIFFUSION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; IN VIVO STUDY; MOUSE; NONHUMAN; SKIN PERMEABILITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; CALCITRIOL; DERMATOLOGIC AGENTS; DRUG DELIVERY SYSTEMS; EMOLLIENTS; EMULSIONS; MICE; MICE, HAIRLESS; SKIN; SKIN ABSORPTION; SOLVENTS;

EID: 79960346092     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.550299     Document Type: Article

References (30)

1. Polano MK, Bonsel J, van der Meer BJ. (1950). Te relation between the efect of topical irritants and the ointment bases in which they are applied to the skin. Dermatologica, 101:69-79.
2. Hadgraft J. (1989). Formulation of anti-infammatory agents. In: Hensby C, Lowe NJ (eds.), Nonsteroidal anti-infammatory drugs. Pharmacol. Skin. Basel, Karger, 2, 21-43.
3. Pershing LK, Silver BS, Krueger GG, Shah VP, Skelley JP. (1992). Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay. Pharm Res, 9:45-51.
4. Christian STT, Smith EW. (2002). Ointment, cream, and lotion as topical drug delivery system. In: Robert L, Bronaugh HI (eds.), Topical absorption of dermatological products. Fragrance Journal, Tokyo.
5. Smith EW, Meyer E, Haigh JM. (1990). Blanching activities of betamethasone formulations. Te efect of dosage form on topical drug availability. Arzneimittelforschung, 40:618-621. (Pubitemid 20177481)
6. Haigh JM, Smith EW, Meyer E, Fassihi R. (1992). Infuence of the oil phase dispersion in a cream base on the in vivo release of betamethasone 17-valerate. S.T.P. Pharma Sciences, 2:259-264.
7. Richard B, Stoughton MD. (1987). Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol, 123:1312-1314.
8. Stoughton RB, Wullich K. (1989). Te same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity? Arch Dermatol, 125:1509-1511. (Pubitemid 19280881)
9. Somerma S. (1980). Te chamber vasoconstrictor assay. I. Comparison with occluded and unoccluded tests using four corticosteroids. Clin Exp Dermatol, 5:191-196. (Pubitemid 10082156)
10. Smith EW, Meyer E, Haigh JM, Maibach HI. (1991). Te human skin blanching assay for comparing topical corticosteroid availability. J Dermatol Treat, 2:69-72.
11. Gao HY, Li Wan Po A. (1994). Topical formulations of fuocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution afect activity? Eur J Clin Pharmacol, 46:71-75. (Pubitemid 24067592)
12. Trottet L, Owen H, Holme P, Heylings J, Collin IP, Breen AP et al. (2005). Are all aciclovir cream formulations bioequivalent? Int J Pharm, 304:63-71. (Pubitemid 41427650)
13. Tsai J, Chuang S, Hsu M, Sheu H. (1999). Distribution of salicylic acid in human stratum corneum following topical application in vivo: a comparison of six diferent formulations. Int J Pharm, 188: 145-153. (Pubitemid 29486717)
14. Ostrenga J, Steinmetz C, Poulsen B. (1971a). Signifcance of vehicle composition. I. Relationship between topical vehicle composition, skin penetrability, and clinical efcacy. J Pharm Sci, 60:1175-1179.
15. Ostrenga J, Steinmetz C, Poulsen B, Yett S. (1971b). Signifcance of vehicle composition. II. Prediction of optimal vehicle composition. J Pharm Sci, 60:1180-1183.
16. Ostrenga J, Steinmetz C, Poulsen B, Yett S. (1971c). Signifcance of vehicle composition. II. Prediction of optimal vehicle composition. J Pharm Sci, 60:1180-1183.
17. Hadgraft J. (1999). Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm, 184:1-6. (Pubitemid 29308990)
18. Kumar S, Malick AW, Meltzer NM, Mouskountakis JD, Behl CR. (1992). Studies of in vitro skin permeation and retention of a leukotriene antagonist from topical vehicles with a hairless guinea pig model. J Pharm Sci, 81:631-634. (Pubitemid 23006786)
19. Adnan A., Zeenat IK, Aqil M, Farhan JA, Roop KK, Sushama T. (2009). Microemulsions as a surrogate carrier for dermal drug delivery. Drug Dev Ind Pharm, 35:525-547.
20. Rachna P, Sneh A, Roop KK, Amit KD, Veena K. (2009). Studies on in vitro and in vivo transdermal fux enhancement of methotrexate by a combinational approach in comparison to oral delivery. Drug Dev Ind Pharm, 35:1281-1292.
21. Karimunnisa SS, Bothiraja C, Atmaram PP. (2010). Studies on nonionic surfactant bilayer vesicles of ciclopirox olamine. Drug Dev Ind Pharm, 36:946-953.
22. Marchiori ML, Lubini G, Dalla Nora G, Friedrich RB, Fontana MC, Ourique AF et al. (2010). Hydrogel containing dexamethasone-loaded nanocapsules for cutaneous administration: preparation, characterization, and in vitro drug release study. Drug Dev Ind Pharm, 36:962-971.
23. Yamamoto H. (2007). Application handbook of solubility parameters. Jouhoukikou, Tokyo.
24. Liron Z, Cohen S. (1984). Percutaneous absorption of alkanoic acids II: Application of regular solution theory. J Pharm Sci, 73:538-542. (Pubitemid 14134335)
25. Hada N, Hasegawa T, Takahashi H, Ishibashi T, Sugibayashi K. (2005). Cultured skin loaded with tetracycline HCl and chloramphenicol as dermal delivery system: mathematical evaluation of the cultured skin containing antibiotics. J Control Release, 108:341-350. (Pubitemid 41608666)
26. Yamaguchi K, Mitsui T, Yamamoto T, Shiokawa R, Nomiyama Y, Ohishi N et al. (2006). Analysis of in vitro skin permeation of 22-oxacalcitriol having a complicated metabolic pathway. Pharm Res, 23:680-688.
27. Higuchi T. (1960). Physical chemical analysis of percutaneous absorption process from creams and ointment. J Soc Cosm Chem, 11:85-97.
28. Smith EW, Christian STT, Tassopoulos A, Maibach HI. (2002). Skin applied base ∼comprehensive approach∼. In: Robert L, Bronaugh HI. (eds.), Topical absorption of dermatological products. Fragrance Journal, Tokyo.
29. Hadgraft J. (2001). Modulation of the barrier function of the skin. Skin Pharmacol Appl Skin Physiol, 14 Suppl 1:72-81. (Pubitemid 34299167)
30. Dias M, Hadgraft J, Lane ME. (2007). Infuence of membrane-solvent-solute interactions on solute permeation in model membranes. Int J Pharm, 336:108-114. (Pubitemid 46551559)